Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion ...

GRO Biosciences has ended the week with an extra $60.3 million in the bank, which the protein therapeutics-focused biotech ...

Artiva Biotherapeutics has upsized its IPO to $167 million as the allogeneic natural killer (NK) cell therapy prepares to ...

As Intuitive Surgical continues to roll out its latest da Vinci robot, following its launch in March, the company warned that ...

As Gilead hunts for a successor, Parsey will continue to serve as chief medical officer until the first quarter of 2025.

Since the first patient received allogeneic hematopoietic cell transplantation (allo-HCT) to treat thalassemia, an inherited ...

The breakout success of GLP-1 drugs by Novo Nordisk and Eli Lilly has persuaded many of their Big Pharma peers to enter their ...

Though his real name isn’t known, there’s no doubt that he’ll go down in history. | Though his real name isn’t known, there’s ...

Low double-digit growth in quarterly medical device sales has pushed Abbott to nudge up its earnings projections for the year ...

Now operating on its own, Grail is moving forward with large-scale clinical trials for its Galleri multi-cancer early ...

After mulling over the data from a failed phase 2 trial, Johnson & Johnson has decided to halt development of its Addex ...

The FDA has scotched Agenus’ plans to seek accelerated approval for a colorectal cancer combination, prompting the biotech to ...